Healthcare - Biotechnology - NASDAQ - US
$ 6.69
-11.6 %
$ 427 M
Market Cap
-5.82
P/E
INCOME STATEMENT
0
REVENUE
-41.8 M
OPERATING INCOME
-36.9 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Larimar Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 311 K |
| Gross Profit | -311 K |
| Operating Expenses | 41.8 M |
| Operating Income | -41.8 M |
| Other Expenses | -4.81 M |
| Net Income | -36.9 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | ||||||||||
| Cost Of Revenue | 0.3 | 0.3 | 0.3 | 0.2 | 78 K | 0.3 | 0.2 | 0.2 | 70 K | 0 |
| Gross Profit | (0.3) | (0.3) | (0.3) | (0.2) | 78 K | (0.3) | (0.2) | (0.2) | 70 K | 0 |
| OPERATING INCOME | ||||||||||
| Operating Expenses | 41.8 | 36.5 | 50.5 | 42.8 | 23.2 | 62.5 | 53.7 | 56.9 | 73.7 | 35.5 |
| Selling, General and Administrative Expenses | 14.1 | 12.3 | 12.1 | 11.4 | 2.4 | 12.9 | 11.9 | 17.1 | 19.1 | 8.1 |
| Research and Development Expenses | 27.4 | 24.2 | 38.4 | 31.4 | 20.8 | 49.5 | 41.7 | 39.8 | 54.6 | 27.4 |
| Operating Income | (41.8) | (36.5) | (50.5) | (42.8) | (23.2) | (62.7) | (53.9) | (57.1) | (73.8) | (35.5) |
| PRE-TAX INCOME | ||||||||||
| Interest Income Expense | 0 | (0.3) | 0 | 0 | (1.8) | (0.2) | 1.0 | 0.3 | (0.5) | (0.9) |
| Total Other Income | 4.8 | 1.2 | (0.2) | 0.3 | 82 K | (0.2) | 0.9 | (1.1) | (0.5) | (1.0) |
| Pre-Tax Income | (36.9) | (35.4) | (50.6) | (42.5) | (23.1) | (63.0) | (52.9) | (58.2) | (74.3) | (36.6) |
| NET INCOME | ||||||||||
| Tax Provision | 0 | (1.2) | (0.3) | (0.2) | 93.9 K | (1.6) | (0.9) | (0.3) | (0.9) | 0 |
| Net Income | (36.9) | (34.2) | (50.3) | (42.3) | (23.1) | (61.4) | (52.0) | (57.9) | (74.3) | (36.6) |
| EPS | 0.84 | 1.33 | 2.93 | 3.56 | 2.51 | 22.9 | 22.8 | 25.4 | 33.3 | 15.1 |